Original research
Management of breathlessness in patients with cancer: ESMO Clinical Practice Guidelines

https://doi.org/10.1136/esmoopen-2020-001038Get rights and content
Under a Creative Commons license
open access
clinical practice guidelines
breathlessness
dyspnoea
palliative care
respiratory

Cited by (0)

Funding: No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds.

Competing interests: DH has reported research grants from National Cancer Institute (US), National Institute of Nursing Research (US), American Cancer Society, Helsinn, Insys, Teva and Depomed. MM has reported research grants from National Institute for Health Research and consultancy fees from Helsinn and Fresenius Kabi. MJ has received institutional payments for clinical consultancy to Mayne Pharma and honoraria from Novartis. ME has reported honoraria from AstraZeneca, Boehringer Ingelheim, Novartis and Roche. SS has reported research grants from Federal Ministry of Education and Research in Germany and from the European Commission. CR has received funding from InPharm, Kyowa Kirin, Amgen Europe and Molteni SpA. ACO and SB have declared no potential conflicts of interest.

Patient consent for publication: Not required.

Provenance and peer review: ESMO-commissioned faculty review completed; externally peer reviewed.

Data availability statement: All published ESMO Clinical Practice Guidelines can be found on https://www.esmo.org/guidelines.

Supplemental material: This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Approved by the ESMO Guidelines Committee: July 2015. Last update October 2020. This publication supersedes the previously published version – Ann Oncol 2015; 26 (suppl 5): v169–v173.